Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3)

• Status: Completed
• Trial end date: 2018-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a one-year pilot, interventional, prospective, single arm, non-randomized, multicentric (3 centers) controlled study that aims to evaluate the response of type 3 choroidal neovascularization to treatment by Aflibercept following a classic protocol.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Poitiers University Hospital
• Treatments: Aflibercept

Criteria

Inclusion Criteria:

• Males or females aged more than 50 years

• Patients with type 3 choroidal neovascularization assessed on FA, ICG and OCT

• Exudation on SD-OCT scans defined by intraretinal cysts or subretinal fluid.

• Best Corrected Visual Acuity at inclusion between 24 and 78 letters (ETDRS)

• Media clarity, pupillary dilation and patient cooperation sufficient to allow fundus photographs of adequate quality

Exclusion Criteria:

• Any contraindications as reported in the labelling of Aflibercept (Eylea®): Ocular or periocular infection, Active intraocular inflammation or Hypersensitivity.

• Any previous history of intravitreal injections in the study eye for exudative AMD

• Any secondary chorioretinal anastomosis due to retinal scar or fibrosis

• Any history of vitrectomy

• Media opacities preventing accurate imaging of the retina (cataract)

• Any other retinal disorder possibly associated with type 3 CNV (epiretinal membrane, macular hole)

• Confirmed intraocular pressure ≥25 mmHg or non-stable glaucoma.